Therapeutic Inertia in 19 Percent With T2DM, HbA1c ≥8 Percent

This article originally appeared here.
Share this content:
Therapeutic Inertia in 19 Percent With T2DM, HbA1c ≥8 Percent
Therapeutic Inertia in 19 Percent With T2DM, HbA1c ≥8 Percent

WEDNESDAY, July 5, 2017 (HealthDay News) -- Therapeutic inertia occurs in 19.1 percent of patients with type 2 diabetes with hemoglobin A1c (HbA1c) ≥8 percent on two or more non-insulin antidiabetic drugs (NIADs), according to a study published online June 28 in Diabetes, Obesity and Metabolism.

Manel Mata-Cases, M.D., Ph.D., from the Institut Universitari d'Investigació en Atenció Primària Jordi Gol in Barcelona, Spain, and colleagues examined the patterns and predictors of treatment intensification in patients with type 2 diabetes.

The researchers found that 26.2 percent of the 23,678 patients with HbA1c ≥7 percent were censored without treatment intensification after a median follow-up of 4.2 years. Therapeutic inertia, defined as no intensification if Hba1c was ≥8 percent at baseline or during follow-up, was seen in 18.1 percent of the 12,730 patients with HbA1c of ≥8 percent at baseline or during follow-up. The mean HbA1c values at initiation of insulin and NIAD were 9.4 ± 1.5 and 8.7 ± 1.3 percent, respectively, in the overall cohort. The median time to first intensification was 17.1 and 10.1 months in patients with HbA1c 8.0 to 9.9 percent and >10 percent, respectively. HbA1c values 8.0 to 9.9 percent and >10 percent and diabetes duration ≥20 years were variables strongly associated with intensification (subhazard ratios, 1.7, 2.5, and 1.25, respectively).

"Both the HbA1c thresholds and the time until therapy intensification exceeded current recommendations," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »